EVIDENCE PROFILE / PUBLISHED
Cagrilintide
Cagrilintide is a long-acting amylin analogue under clinical development. A multinational phase 2 dose-finding trial randomized 706 participants to cagrilintide doses, 99 to liraglutide, and 101 to placebo and reported weight-loss and tolerability outcomes.
Evidence at a glance
- Human
- LimitedOne large randomized phase 2 trial.
- Animal/cell
- Not rated
- Approved medicine
- Not rated
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Research examines satiety signaling, body weight, metabolic endpoints, and combination regimens.
Identity
Cagrilintide is a long-acting amylin analogue under clinical development.
Biological mechanism or research interest
Research examines satiety signaling, body weight, metabolic endpoints, and combination regimens.
Verified approved human uses
No approved standalone cagrilintide medicine was verified in the reviewed sources.
Investigational human evidence
A multinational phase 2 dose-finding trial randomized 706 participants to cagrilintide doses, 99 to liraglutide, and 101 to placebo and reported weight-loss and tolerability outcomes.
Popular claims versus demonstrated findings
Phase 2 weight findings do not prove broad safety, long-term outcomes, or effectiveness of a 5 mg catalogue vial.
Human versus animal or cell evidence
Amylin-receptor biology supports satiety research but cannot establish clinical benefit by itself.
Limitations and known risks
Gastrointestinal adverse effects, long-term outcomes, combination effects, material identity, and final regulatory benefit-risk remain unresolved.
